ANGO

SEC source: 0001140361-17-043659 · doc1.xml · nonDerivative · entry 2

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,703

SEC source: 0001140361-17-043659 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-043208 · doc1.xml · derivative · entry 5

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,409 shares

Expires 2020-08-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/6/2014, 8/6/2015, 8/6/2016 and 8/6/2017, respectively.

SEC source: 0001140361-17-043208 · doc1.xml · derivative · entry 4

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2019-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/3/2013, 8/3/2014, 8/3/2015 and 8/3/2016, respectively.

SEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 3

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,754

SEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 2

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 1

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-035496 · doc1.xml · derivative · entry 6

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2018-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-third of the shares each became exercisable on 08/03/2012, 08/03/2013 and 08/03/2014, respectively.

SEC source: 0001140361-17-035496 · doc1.xml · derivative · entry 5

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2017-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares each became exercisable on 10/19/2011, 10/19/2012 and 10/19/2013, respectively.

SEC source: 0001140361-17-035496 · doc1.xml · nonDerivative · entry 4

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,817

SEC source: 0001140361-17-035496 · doc1.xml · nonDerivative · entry 3

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,288

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-035496 · doc1.xml · nonDerivative · entry 2

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,288

SEC source: 0001140361-17-035496 · doc1.xml · nonDerivative · entry 1

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-030645 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,452

F1 · shares: The exempt disposition of 495 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on August 6, 2013.

SEC source: 0001140361-17-030641 · doc1.xml · nonDerivative · entry 1

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,754

F1 · shares: The exempt disposition of 502 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on August 6, 2013.

SEC source: 0001140361-17-029179 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,817

F2 · shares: The exempt disposition of 1,958 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-17-029177 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,324

F2 · shares: The exempt disposition of 282 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 3

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,134

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029118 · doc1.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,292

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029179 · doc1.xml · derivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,184

Underlying: Common Stock · 44,184 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029179 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,627

Underlying: Common Stock · 77,627 shares

Expires 2027-07-26

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029179 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,775

F1 · shares: This acquisition of 22,092 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 22,092 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029096 · doc1.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,976

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029115 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,127

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029110 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,974

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029092 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,576

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029177 · doc1.xml · derivative · entry 4

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,684

Underlying: Common Stock · 6,684 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029177 · doc1.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,744

Underlying: Common Stock · 11,744 shares

Expires 2027-07-26

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029177 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,606

F1 · shares: This acquisition of 3,342 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,342 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029112 · doc1.xml · nonDerivative · entry 1

LaPorte Steve · CIK 0001340404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,177

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029104 · doc1.xml · nonDerivative · entry 1

Gould Kevin J · CIK 0001504093 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,064

F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018.

SEC source: 0001140361-17-029089 · doc1.xml · derivative · entry 5

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,296

Underlying: Common Stock · 7,296 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029089 · doc1.xml · derivative · entry 4

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,818

Underlying: Common Stock · 12,818 shares

Expires 2027-07-26

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029089 · doc1.xml · nonDerivative · entry 3

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,256

F3 · shares: This acquisition of 3,648 shares of Common Stock represents 3,648 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029083 · doc1.xml · derivative · entry 3

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,387

Underlying: Common Stock · 12,387 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029083 · doc1.xml · derivative · entry 2

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,762

Underlying: Common Stock · 21,762 shares

Expires 2027-07-26

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029083 · doc1.xml · nonDerivative · entry 1

Greiner Michael · CIK 0001520392 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,193

F1 · shares: This acquisition of 6,193 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,193 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029085 · doc1.xml · derivative · entry 3

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,477

Underlying: Common Stock · 7,477 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029085 · doc1.xml · derivative · entry 2

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,137

Underlying: Common Stock · 13,137 shares

Expires 2027-07-26

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029085 · doc1.xml · nonDerivative · entry 1

Simpson Robert Arthur · CIK 0001706163 · SVP/GM, Global Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,739

F1 · shares: This acquisition of 3,739 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,739 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029081 · doc1.xml · derivative · entry 5

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,409

Underlying: Common Stock · 7,409 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029081 · doc1.xml · derivative · entry 4

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,018

Underlying: Common Stock · 13,018 shares

Expires 2027-07-26

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029081 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,947

F3 · shares: This acquisition of 3,705 shares of Common Stock represents 3,705 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029123 · doc1.xml · derivative · entry 4

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2017-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for 33 1/3% of the total number of shares each became exercisable on 8/3/2011, 8/3/2012 and 8/3/2013.

SEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 2

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,158

SEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 1

GOLD JEFFREY · CIK 0000938659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-029089 · doc1.xml · nonDerivative · entry 2

Richard Stark · CIK 0001539142 · SVP, GM - Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,608

F2 · shares: The exempt disposition of 432 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014.

SEC source: 0001140361-17-029081 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,242

F2 · shares: The exempt disposition of 437 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014.

SEC source: 0001140361-17-030639 · doc1.xml · derivative · entry 3

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2017-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options for one-third of the shares each became exercisable on 08/03/2011, 08/03/2012 and 08/03/2013, respectively.

SEC source: 0001140361-17-030639 · doc1.xml · nonDerivative · entry 2

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,248